Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activate Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia

Karina Calvopiña; Punyawee Dulyayangkul; Matthew B Avison

doi:10.1128/AAC.01524-19

Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activate Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia

Karina Calvopiña, Punyawee Dulyayangkul, Matthew B Avison^*

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

12 Citations (Scopus)

64 Downloads (Pure)

Abstract

Aminoglycoside resistance in Stenotrophomonas maltophilia is multifactorial, but the most significant mechanism is overproduction of the SmeYZ efflux system. By studying laboratory selected mutants and clinical isolates, we show here that damage to the 50S Ribosomal protein L1 (RplA) activates SmeYZ production. We also show that gentamicin and minocycline, which target the ribosome, induce expression of smeYZ These findings explain the role of SmeYZ in both intrinsic and mutationally acquired aminoglycoside resistance.

Original language	English
Article number	e01524-19
Number of pages	5
Journal	Antimicrobial Agents and Chemotherapy
Volume	64
Issue number	2
DOIs	https://doi.org/10.1128/AAC.01524-19
Publication status	Published - 27 Jan 2020

Access to Document

10.1128/AAC.01524-19

Full-text PDF (accepted author manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via the American Society for Microbiology at https://aac.asm.org/content/64/2/e01524-19. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 184 KB

Handle.net

Persistent link

One Health Drivers of Antibacterial Resistance in Thailand
Avison, M. B. (Principal Investigator), Lambert, H. S. (Co-Investigator) & Al Husein, N. (Researcher)
1/05/18 → 31/01/22
Project: Research
FEC 202022 - Detecting antibiotic resistance proteins in clinical samples using proteomics.
Avison, M. B. (Principal Investigator)
13/04/16 → 12/10/17
Project: Research

Cite this

@article{da3abbf3617b4019bdbeca04fe050116,

title = "Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activate Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia",

abstract = "Aminoglycoside resistance in Stenotrophomonas maltophilia is multifactorial, but the most significant mechanism is overproduction of the SmeYZ efflux system. By studying laboratory selected mutants and clinical isolates, we show here that damage to the 50S Ribosomal protein L1 (RplA) activates SmeYZ production. We also show that gentamicin and minocycline, which target the ribosome, induce expression of smeYZ These findings explain the role of SmeYZ in both intrinsic and mutationally acquired aminoglycoside resistance.",

author = "Karina Calvopi{\~n}a and Punyawee Dulyayangkul and Avison, {Matthew B}",

year = "2020",

month = jan,

day = "27",

doi = "10.1128/AAC.01524-19",

language = "English",

volume = "64",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "2",

}

Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activate Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia. / Calvopiña, Karina; Dulyayangkul, Punyawee; Avison, Matthew B.
In: Antimicrobial Agents and Chemotherapy, Vol. 64, No. 2, e01524-19, 27.01.2020.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activate Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia

AU - Calvopiña, Karina

AU - Dulyayangkul, Punyawee

AU - Avison, Matthew B

PY - 2020/1/27

Y1 - 2020/1/27

N2 - Aminoglycoside resistance in Stenotrophomonas maltophilia is multifactorial, but the most significant mechanism is overproduction of the SmeYZ efflux system. By studying laboratory selected mutants and clinical isolates, we show here that damage to the 50S Ribosomal protein L1 (RplA) activates SmeYZ production. We also show that gentamicin and minocycline, which target the ribosome, induce expression of smeYZ These findings explain the role of SmeYZ in both intrinsic and mutationally acquired aminoglycoside resistance.

AB - Aminoglycoside resistance in Stenotrophomonas maltophilia is multifactorial, but the most significant mechanism is overproduction of the SmeYZ efflux system. By studying laboratory selected mutants and clinical isolates, we show here that damage to the 50S Ribosomal protein L1 (RplA) activates SmeYZ production. We also show that gentamicin and minocycline, which target the ribosome, induce expression of smeYZ These findings explain the role of SmeYZ in both intrinsic and mutationally acquired aminoglycoside resistance.

U2 - 10.1128/AAC.01524-19

DO - 10.1128/AAC.01524-19

M3 - Article (Academic Journal)

C2 - 31712205

SN - 0066-4804

VL - 64

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 2

M1 - e01524-19

ER -

Mutations in Ribosomal Protein RplA or Treatment with Ribosomal Acting Antibiotics Activate Production of Aminoglycoside Efflux Pump SmeYZ in Stenotrophomonas maltophilia

Abstract

Access to Document

Handle.net

Fingerprint

Projects

One Health Drivers of Antibacterial Resistance in Thailand

FEC 202022 - Detecting antibiotic resistance proteins in clinical samples using proteomics.

Cite this